Viatris to acquire Pacira BioSciences for $36.50/share in cash

Viatris announced a definitive merger agreement to acquire all outstanding shares of Pacira BioSciences for $36.50 per share in cash via a tender offer followed by merger. This is a material M&A transaction that will increase Viatrs' debt/capital obligations and dilute shareholder value through a large cash outlay, while Pacira shareholders receive a fixed price offer representing the deal's value realization.

Viatris agreed to buy Pacira BioSciences for $36.50 per share in cash. Viatris stock typically falls on large acquisitions because the buyer spends cash or takes on debt, while Pacira shareholders get a set price.